An update on the potential risks of over-inflation (spontaneous hyperinflation), acute pancreatitis, and deaths in patients with Orbera and ReShape liquid-filled intragastric balloons used for weight loss in adult patients with obesity.
The FDA recognizes that the need for personal protective equipment (PPE), such as surgical masks, surgical and isolation gowns, and surgical suits, may outpace the supply available to health care organization during the Coronavirus Disease 2019 (COVID-19) outbreak.
QuVa Pharma, Inc. confirms that is working with the U.S. Food and Drug Administration, and voluntarily recalling all lots of R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac) 50 ml in Sodium Chloride-60 ml BD syringe that were prepared using sterile Ketorolac being recalled by Fresenius Kabi
Mon, 27 Apr 2020 00:00:00 -0400
FDA is concerned that hydroxychloroquine and chloroquine are being used inappropriately to treat non-hospitalized patients for coronavirus disease (COVID-19) or to prevent that disease.
Trividia Health, Inc. today announced it is initiating a nationwide voluntary recall of one (1) TRUE METRIX® AIR Blood Glucose Meter distributed in the United States to one customer (AssuraMed). The meter was not packaged into storebrand or retail branded packaging.
Dear reader,
Today we are embarking on a journey in the area of information on drug prescriptionin pregnancy with particular attention to the assessment of the embryo-foetal risk profile. This is the first in a series of articles to be published in the coming months.
In this first contribution, special emphasis is placed on the most prescribed drugs based on the 2018 OsMed report and the associated risk profile assessment. In subsequent articles, a number of classes of drugs, starting with antihypertensives, will be explored in more detail.
Caro lettore,
oggi intraprendiamo un cammino nell’ambito dell’informazione sulla prescrizione dei farmaci in gravidanza con particolare attenzione alla valutazione del profilo di rischio embrio-fetale. Questo è il primo di una serie di articoli che verranno pubblicati nei prossimi mesi.
In questo primo contributo viene data particolare importanza ai principi attivi più prescritti sulla base del rapporto OsMed del 2018, con la relativa valutazione del profilo di rischio. Negli articoli successivi verranno approfondite alcune classi di farmaci a partire dagli antipertensivi.
Fresenius Kabi USA, LLC is voluntarily recalling 13 lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial and Ketorolac Tromethamine Injection, USP, 60 mg/2 mL (30 mg/mL), 2 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter
Braun Medical Inc. (B. Braun) is voluntarily recalling one (1) lot of 2g Ceftazidime for Injection USP (2g) and Dextrose for Injection USP (50 ml) in Duplex® Container to the hospital/user level.. During stability testing of Batch H8J812, test results were found to exceed the specification limits fo
80.211.154.110
